Breast Cancer, Ductal Carcinoma
Conditions
Keywords
Breast Cancer, Nipple Area Complex, Mastectomy, Radiation Therapy, Nipple-Sparing, Breast Reconstruction
Brief summary
The purpose of this research study is to see if a participant's nipple and areola can be safely preserved by adding radiation to these areas after a nipple-sparing mastectomy and immediate breast reconstruction.
Interventions
PROCEDURENipple-Sparing Mastectomy
Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
PROCEDUREBreast Reconstruction
Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
PROCEDUREAxillary Surgery
Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
RADIATIONProphylactic Nipple-Areolar Complex RT
Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
Sponsors
University of Miami
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1 dose-escalation/de-escalation.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed in-situ or invasive breast carcinoma. * Tis, T1, T2 invasive or non-invasive carcinoma of the breast; lesion less than 4 cm. * Unifocal, multifocal or multicentric breast cancers that can be removed by nipple sparing mastectomy with negative surgical margins. * No extensive intraductal component or patient with distant metastases. * Patients must be \> 18 years of age. * No concomitant or history of nipple discharge or skin involvement. * No prior history of malignancy (less than 5 years prior to study entry), except non-melanomatous skin cancer. * No prior history of radiation to the chest. * No collagenous disease (systemic lupus erythematosis, scleroderma, dermatomyositis)No previous non-hormonal therapy including radiation or chemotherapy for current breast cancer. * No patients with Paget's disease of the nipple. * No patients with co-existing medical conditions with life expectancy \< 2 years. * No pregnant or lactating women. * Eastern Cooperative Oncology Group (ECOG) 0 - 2. * Signed study-specific informed consent form prior to the study entry.
Exclusion criteria
* Retroareolar breast cancer lesions within one cm, depth from the skin surface. * Concomitant or history of nipple discharge or skin involvement. * Patient with distant metastases. * Patient with extensive intraductal carcinoma. * Any previously irradiated ipsilateral breast cancer. * Patients with Paget's disease of the nipple. * Patients with collagenous diseases, as systemic lupus erythematosis, scleroderma or dermatomyositis. * Other malignancy, except nonmelanomatous skin cancer, less than 5 years prior to participation in this study. * Patients who are pregnant or lactating due to potential exposure of the fetus to RT and unknown effects of RT to lactating females. * Positive surgical margins following nipple sparing mastectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of Prophylactic NAC Irradiation. | Up to 13 weeks | The recommended Phase II dose will be reported as the MTD at which only 0 or 1 out of 6 participants experiences dose limiting toxicity (DLT). DLT will be reported as any of the following: Grade 4 skin rash or pain, NAC necrosis, any toxicity requiring interruption of NAC irradiation greater than 2 weeks or any grade 4 or 5 treatment related toxicity. Toxicity will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cosmetic Outcome | 12 months | Cosmetic Outcome will be reported as the number of participants in each of the 4 cosmetic outcome category ordinal scale. The 4 cosmetic outcome category scales are excellent, good, fair and poor. Both physician and patient's evaluation will be reported. |
| Disease-Free Survival Rate in Study Participants | Up to 5 years | Disease-free survival rate in study participants will be assessed. Disease-free survival is defined from the date of surgery until the date of documented recurrence (local or distant) or breast cancer-related death, whichever occurs first. Patients who die without documentation of recurrence will be considered to have had disease recurrence at the time of death, unless there is documented evidence that no recurrence occurred before death. |
| Overall Survival Rate in Study Participants | Up to 5 years | Overall Survival rate in study participants will be assessed. Overall survival is the defined from the date of surgery until the date of death due to any cause. In the absence of death, follow-up time will be censored by the date of last contact.. |
| Recurrence Rate in Study Participants | Up to 5 years | Rate of disease recurrence in study participants. The definition of local recurrence is histologic evidence of recurrent carcinoma, either invasive or non-invasive in the nipple-areola complex in the ipsilateral breast. Clinical evidence of carcinoma by physical exam and/or mammograms/MRI will not be evidence of local recurrence until biopsy proof. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORCristiane Takita, MD
University of Miami
Participant flow
Pre-assignment details
Participants undergo NAC-Sparing Mastectomy, and then receive prophylactic radiation therapy according to a dose-escalation/de-escalation design, the first cohort of 2 to 6 patients starting at dose level II (10 Fractions of 2.5 Gy). If 2 or more participants experience dose-limiting toxicities at the starting dose level (dose level II), then de-escalation occurs to dose level I (10 Fractions of 2.0 Gy) for the next cohort of 2 to 6 participants. No participants were assigned to dose level I.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1 MTD NAC RT Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:
* Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy
* Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy
* Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy
* Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy
Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).
Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT. | 21 |
| Total | 21 |
Baseline characteristics
| Characteristic | Phase 1 MTD NAC RT |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 20 Participants |
| Region of Enrollment United States | 21 participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 6 | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 12 / 21 | 6 / 6 | 6 / 6 | 6 / 6 |
| serious Total, serious adverse events | 1 / 21 | 0 / 6 | 0 / 6 | 0 / 6 |
Outcome results
Primary
Maximum Tolerated Dose (MTD) of Prophylactic NAC Irradiation.
The recommended Phase II dose will be reported as the MTD at which only 0 or 1 out of 6 participants experiences dose limiting toxicity (DLT). DLT will be reported as any of the following: Grade 4 skin rash or pain, NAC necrosis, any toxicity requiring interruption of NAC irradiation greater than 2 weeks or any grade 4 or 5 treatment related toxicity. Toxicity will be evaluated by treating physician using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
Time frame: Up to 13 weeks
Population: A total of 18 participants at dose-escalating study design (6 participants at each dose level - Levels II, III and IV) who received prophylactic NAC RT after nipple-sparing mastectomy were evaluated to assess the MTD/Recommended Phase II dose.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Prophylactic NAC RT After Nipple-Sparing Mastectomy | Maximum Tolerated Dose (MTD) of Prophylactic NAC Irradiation. | 35 Gy (grays) |
Secondary
Cosmetic Outcome
Cosmetic Outcome will be reported as the number of participants in each of the 4 cosmetic outcome category ordinal scale. The 4 cosmetic outcome category scales are excellent, good, fair and poor. Both physician and patient's evaluation will be reported.
Time frame: 12 months
Secondary
Disease-Free Survival Rate in Study Participants
Disease-free survival rate in study participants will be assessed. Disease-free survival is defined from the date of surgery until the date of documented recurrence (local or distant) or breast cancer-related death, whichever occurs first. Patients who die without documentation of recurrence will be considered to have had disease recurrence at the time of death, unless there is documented evidence that no recurrence occurred before death.
Time frame: Up to 5 years
Secondary
Overall Survival Rate in Study Participants
Overall Survival rate in study participants will be assessed. Overall survival is the defined from the date of surgery until the date of death due to any cause. In the absence of death, follow-up time will be censored by the date of last contact..
Time frame: Up to 5 years
Secondary
Recurrence Rate in Study Participants
Rate of disease recurrence in study participants. The definition of local recurrence is histologic evidence of recurrent carcinoma, either invasive or non-invasive in the nipple-areola complex in the ipsilateral breast. Clinical evidence of carcinoma by physical exam and/or mammograms/MRI will not be evidence of local recurrence until biopsy proof.
Time frame: Up to 5 years